Study looks at safety of imatinib, nilotinib for leukemia patients | Treatment-naive adult patients with HIV benefit from doravirine | Scientists identify 40 potential drug targets in multiple myeloma study
April 13, 2018
News for the transfusion medicine and cellular therapy community
Researchers evaluated outcomes of 11 patients with chronic myeloid leukemia who had no history of cardiovascular disease and been treated with either imatinib or nilotinib and had never been treated with tyrosine kinase inhibitors. The study in the journal Cardiovascular Toxicity found that treatment with imatinib or nilotinib for 12 months was not associated with reduced cardiovascular function.
Registration open: FREE program in Kansas City, KS Join us for a FREE Transfusion Science Educational Course (TSEC) in Kansas City, KS on May 17-18, 2018, presented by world renowned experts in transfusion medicine. Participants will receive 12 CEUs. Contact us at TSEC@grifols.com or call 833-835-3439.
A study comparing the doravirine and ritonavir-boosted darunavir in adult patients with HIV who were treatment-naive found that doravirine was just as effective as darunavir, with 84% of 383 patients in the doravirine group having plasma HIV-1 RNA less than 50 copies per mL versus 80% in the darunavir group. The findings were published in the journal The Lancet HIV last month.
Forty genes have been identified by investigators from London's Institute of Cancer Research that could become potential therapeutic targets. As reported in the journal Leukemia, the researchers were able to pinpoint coding and noncoding mutations linked to the development of multiple myeloma while examining whole-genome sequencing data from 765 patients.
Early results of studies using CRISPR gene editing technology to cure diseases in monkeys are promising, particularly in diseases that involve mutation of a single gene, but most of the research has been on cells and healthy monkeys. The next step is for researchers to use gene editing to develop nonhuman primate models of specific diseases to generate real-world evidence that gene editing treatments are effective and safe before they are tried in humans.
Swedish biopharmaceutical firm Wilson Therapeutics was purchased by Alexion Pharmaceuticals for $855 million. Wilson has late-stage, orphan drug- and fast track-tagged WTX101, which is being developed to treat patients with Wilson disease.
The Scottish Medicines Consortium approved for National Health Service use Shire's Revestive, or teduglutide, for pediatric onset short bowel syndrome in children ages 1 to 17, and Sanofi's Kevzara, or sarilumab, for adults with rheumatoid arthritis who do not respond to or are intolerant of standard therapies. The regulator also endorsed two hepatitis C-targeting drugs: Gilead's Vosevi, or sofosbuvir/velpatasvir/voxilaprevir, which is indicated to treat certain adult patients with hepatitis C, and Gilead's Epclusa, or sofosbuvir-velpatasvir, for patients with hepatitis C genotype 1 or 4 infection.
AABB will host an eCast, "Donor Hemovigilance: DonorHART Demo and Recent Findings," on Tuesday, April 17, at 2 p.m. Eastern Time. This program will provide listeners with a demonstration of the DonorHART software program and how facilities can compare their hemovigilance data with others. Speakers will also explore recent findings from the AABB Donor Hemovigilance Program.